PRESENT-DAY APPROACHES TO THE TREATMENT FOR CHRONIC LYMPHATIC LEUKEMIA: APPLICATION OF RITUXIMAB IN CLINICAL PRACTICE
https://doi.org/10.51523/2708-6011.2011-8-2s-20
Abstract
The present-day approaches to the treatment for chronic lymphatic leukemia have been considered, the application of rituximab, monoclonal antibody to СD20-receptors has been grounded. The results of the retrospective analysis and randomized clinical research, dedicated to the assessment of efficacy of rituximab in the combination with chemotherapy in CLL, have been presented. Based on these results, the conclusion about the advantage of immunochemotherapy with rituximab over the chemotherapy in the treatment of CLL patients has been made. It is emphasized, that R-FC mode can be considered as a new first-line therapy standard in CLL patients.
References
1. Johnson, S. [et al.] // Lancet. - 1996. - Vol. 347. - P. 1432-1438.
2. Rai, K. [et al.] // N. Engl J. Med. - 2000. - Vol. 343. - P. 1750-1757.
3. Leporrier, M. [et al.] // Blood. - 2001. - Vol. 98. - P. 2319-2325/
4. Eichhorst, B. [et al.] // Blood. - 2006. - Vol. 107. - P. 885-891.
5. Byrd, J. C. [et al.] // Blood. - 2003. - Vol. 101. - P. 6-14.
6. Hallek, M. H. [et al.] // Lancet. - 2010. - Vol. 376. - P. 1164-1174.
Review
For citations:
Milanovich N.F. PRESENT-DAY APPROACHES TO THE TREATMENT FOR CHRONIC LYMPHATIC LEUKEMIA: APPLICATION OF RITUXIMAB IN CLINICAL PRACTICE. Health and Ecology Issues. 2011;(2S):61-64. (In Russ.) https://doi.org/10.51523/2708-6011.2011-8-2s-20
Views: 217
Email this article 